IL1A and autoimmune disease: IL-1 inhibitors are expected to be clinically beneficial in treating incurable autoimmune disorders, such as SLE and systemic sclerosis, and in managing increased proinflammatory reactions, such as macrophage activation and cytokine release syndromes [182,191].